TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22841455

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol (control)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All doses of alcohol (0.4 g/kg and 0.6 g/kg)
Number of subjects: 96
Study: 21491487

Group type: EXPERIMENTAL
Intervention: Denosumab (DMAb)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study: 18652273

Group type: EXPERIMENTAL
Intervention: ART (atraumatic restorative treatment) approach using Ketac‐Molar (3M ESPE) ionomer cement
Number of subjects: 58
Study: 16867057

Group type: EXPERIMENTAL
Intervention: ECoScreen
Number of subjects: 30

Group type: COMPARATOR
Intervention: RTube
Number of subjects: 30
Study: 12751480

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11098947

Group type: EXPERIMENTAL
Intervention: Hydraulic-pneumatic band system (HB-CPR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumatic vest system (PV-CPR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard manual CPR (S-CPR)
Number of subjects: 0
Study: 8817136

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia buffered with bicarbonate (St Thomas' II solution)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non buffered crystalloid cardioplegia enriched with glutamate and mannitol (Menasché's solution)
Number of subjects: 20
Study: 2073061

Group type: EXPERIMENTAL
Intervention: Ketoconazole foam (2%); applied once
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (excipient); applied once
Number of subjects: 61
Study: 7023597

Group type: EXPERIMENTAL
Intervention: Plastibell device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional dissection technique
Number of subjects: 100
Study: 31856990

Group type: EXPERIMENTAL
Intervention: Silicone corneal shield
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional bandage contact lens (BCL)
Number of subjects: 25
Study: 28414516

Group type: EXPERIMENTAL
Intervention: Amniotic fluid
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Mother's milk
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Mother's odor
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 25910930

Group type: EXPERIMENTAL
Intervention: 2 Hz electroacupuncture (EA) applied at ST36 and GB34 for 30 min on the first two postoperative days, also receiving PCA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Non-point EA identical to EAG except given 1 cm lateral to ST36 and GB34, also receiving PCA
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (CG) using only patient-controlled analgesia (PCA)
Number of subjects: 47
Study: 23223595

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 606

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 606
Study: 21670072

Group type: EXPERIMENTAL
Intervention: Thermostatic mixer valves (TMVs) installed in social housing
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of TMVs
Number of subjects: 1
Study: 19114438

Group type: EXPERIMENTAL
Intervention: High-volume Dysport (500 U/5 mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-volume Dysport (500 U/1 mL)
Number of subjects: 22
Study: 16776749

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 150
Study: 15025796

Group type: EXPERIMENTAL
Intervention: PVI 5-FU 300 mg/m2 daily + mitomycin-C 7 mg/m2 every 6 weeks
Number of subjects: 320

Group type: COMPARATOR
Intervention: Circadian-timed infusion (CTI) of 5-FU starting at 600 mg/m2, reduced to 450 mg/m2 + mitomycin-C 7 mg/m2 every 6 weeks
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: PVI 5-FU + mitomycin-C
Number of subjects: 320

Group type: COMPARATOR
Intervention: CTI 5-FU + mitomycin-C
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: CTI 5-FU
Number of subjects: 320
Study: 11561260

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine 60 microg/kg/min
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 25
Study: 9489592

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Troglitazone 400 mg with cholestyramine 12 g
Number of subjects: 12
Study: 8181888

Group type: EXPERIMENTAL
Intervention: oral propafenone (600 mg as a loading dose followed after 8 h by 300 mg t.i.d.)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: digoxin plus quinidine (total dose, 1350 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 87
Study: 2967304

Group type: EXPERIMENTAL
Intervention: 9 alpha‐fludrocortisone acetate (9 alpha F; 0.6 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31690105

Group type: EXPERIMENTAL
Intervention: Aflibercept (2 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 48
Study: 30200106

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Point-of-care (POC) glucose measurement (Control group)
Number of subjects: 144
Study: 26484407

Group type: EXPERIMENTAL
Intervention: Fasting IGFBP-1
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ratio of IGFBP-1 to fasting insulin
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: IGFBP-1 at time zero
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment-insulin resistance
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Corrected insulin release at the glucose peak (CIRgp)
Number of subjects: 77
Study: 24942282

Group type: EXPERIMENTAL
Intervention: High facilitation and action learning
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard Gold Standards Framework facilitation
Number of subjects: 38
Study: 24141750

Group type: EXPERIMENTAL
Intervention: Encouragement during fusional vergence testing
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Testing order (convergence followed by divergence)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fatigue assessment
Number of subjects: 50
Study: 19946869

Group type: EXPERIMENTAL
Intervention: Educational intervention in group format for informal carers
Number of subjects: 292
Study: 18538047

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 40
Study: 16091912

Group type: EXPERIMENTAL
Intervention: 0.5% nifedipine ointment (n=32) every 8 h for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy (n=32)
Number of subjects: 64
Study: 12655529

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC)
Number of subjects: 120
Study: 10798453

Group type: EXPERIMENTAL
Intervention: Individualized music for 6 weeks followed by classical 'relaxation' music for 6 weeks (30 minutes, two times per week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Classical 'relaxation' music for 6 weeks followed by individualized music for 6 weeks (30 minutes, two times per week)
Number of subjects: 39
Study: 9003975

Group type: EXPERIMENTAL
Intervention: SR-3
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1350407

Group type: EXPERIMENTAL
Intervention: Acitretin (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Etretinate (30 mg daily for the first 4 weeks, then adjusted dose of 10-50 mg/day for 12 weeks)
Number of subjects: 26
Study: 2938614

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g day‐1) with R warfarin (15 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Warfarin enantiomers (15 mg) alone
Number of subjects: 8
Study: 30053967

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100 [200]/25 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 26482723

Group type: EXPERIMENTAL
Intervention: S-1 combined with cisplatin plus concurrent chemoradiotherapy (SCCC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Cisplatin plus concurrent chemoradiotherapy (CCC)
Number of subjects: 144
Study: 25518574

Group type: EXPERIMENTAL
Intervention: 2-week rehabilitation program (Group I, 19 patients, mean age 59.2 ± 8.3 years)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program (Group II, 29 patients, mean age 55.3 ± 7.9 years)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Modified rehabilitation program (Group III, reference group, 21 patients, mean age 65.4 ± 8.2 years)
Number of subjects: 69
Study: 22951813

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Zoledronic Acid (ZA)
Number of subjects: 2046
Study: 20563879

Group type: EXPERIMENTAL
Intervention: Educational and physical program (brief shoulder and neck exercises, relaxation exercise, instructions on reducing parafunction and hyperfunction)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Educational and physical program
Number of subjects: 192
Study: 18460401

Group type: EXPERIMENTAL
Intervention: gel‐to‐foam dentifrice
Number of subjects: 34

Group type: COMPARATOR
Intervention: control dentifrice
Number of subjects: 34
Study: 17177905

Group type: EXPERIMENTAL
Intervention: Active referral 1: specialist referral with four CISS outcalls (1 week, 6 weeks, 3 months, 6 months post diagnosis)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active referral 2: specialist referral with one CISS outcall (1 week post diagnosis)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Passive referral: specialist recommended patient contacts CISS at their initiative
Number of subjects: 100
Study: 12956346

Group type: EXPERIMENTAL
Intervention: Microabrasion treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control slides (no treatment)
Number of subjects: 32
Study: 10715523

Group type: EXPERIMENTAL
Intervention: SBAS4 hepatitis B vaccine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Engerix‐B(TM)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hepatitis B vaccine with alternative formulation on alum
Number of subjects: 150
Study: 8856383

Group type: EXPERIMENTAL
Intervention: Blister suction technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Wick technique
Number of subjects: 15
Study: 1622916

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous ritodrine (0.2 mg/min) in cervical cerclage group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Oral ritodrine (60 mg/day) in amniocentesis group
Number of subjects: 117

Group type: COMPARATOR
Intervention: No ritodrine treatment in both groups
Number of subjects: 117
Study: 6135344

Group type: EXPERIMENTAL
Intervention: Beta blockers (timolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta blockers (metoprolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta blockers (chronic therapy)
Number of subjects: 0
Study: 30883636

Group type: EXPERIMENTAL
Intervention: Beta interferon exposure (at least 6 months)
Number of subjects: 5989

Group type: EXPERIMENTAL
Intervention: Beta interferon exposure (>3 years)
Number of subjects: 5989

Group type: EXPERIMENTAL
Intervention: Beta interferon exposure (6 months to 3 years)
Number of subjects: 5989
Study: 30577872

Group type: EXPERIMENTAL
Intervention: Mobile phone-based sexual and reproductive health services awareness and delivery application
Number of subjects: 0
Study: 27224505

Group type: EXPERIMENTAL
Intervention: Whey protein and creatine co-supplementation (WHEY+CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whey protein supplementation (WHEY)
Number of subjects: 0
Study: 24552755

Group type: EXPERIMENTAL
Intervention: Systane Ultra lubricant eye drops (applied twice a day for 2 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 89
Study: 22746398

Group type: EXPERIMENTAL
Intervention: Indoor ETS exposure (Group 2)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No indoor ETS exposure (Group 1)
Number of subjects: 97
Study: 20647097

Group type: EXPERIMENTAL
Intervention: manual‐dynamic activation group (final rinse 17%EDTA/3%NaOCl + gutta‐percha agitation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sonic‐activation group (final rinse 17%EDTA/3%NaOCl + Endoactivator)
Number of subjects: 50

Group type: COMPARATOR
Intervention: no‐activation group (final rinse with a 27‐gauge needle and 17% EDTA/3% NaOCl)
Number of subjects: 50
Study: 18381469

Group type: EXPERIMENTAL
Intervention: Self-reported CRC screening
Number of subjects: 1280
Study: 16047874

Group type: EXPERIMENTAL
Intervention: Sodium sulfacetamide 10% and sulfur 5% cream with sunscreens
Number of subjects: 152

Group type: COMPARATOR
Intervention: Metronidazole 0.75% cream
Number of subjects: 152
Study: 11929578

Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 33
Study: 9893155

Group type: EXPERIMENTAL
Intervention: Cladribine 0.07 mg/kg/day by subcutaneous injection for 5 consecutive days as six monthly courses for a total cumulative dose of 2.1 mg/kg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8578259

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy plus placebo
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 142
Study: 2134648

Group type: EXPERIMENTAL
Intervention: Ultrasound and preoperative treatment of the neck area
Number of subjects: 0
Study: 30367733

Group type: EXPERIMENTAL
Intervention: Allograft covered with cross‐linked collagen membrane left exposed
Number of subjects: 30

Group type: COMPARATOR
Intervention: Allograft covered with non‐crosslinked collagen membrane with primary closure
Number of subjects: 30
Study: 28651697

Group type: EXPERIMENTAL
Intervention: 0.32% DHA/0.64% ARA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.64% DHA/0.64% ARA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.96% DHA/0.64% ARA
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.00% DHA/0.00% ARA
Number of subjects: 0
Study: 25291977

Group type: EXPERIMENTAL
Intervention: On-site rapid HCV testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-site rapid HCV and HIV testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: No testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Off-site HCV testing referral
Number of subjects: 0
Study: 23530672

Group type: EXPERIMENTAL
Intervention: Pharmacist led workshops (4 weekly 1-hour workshops covering pharmacokinetics, pharmacodynamics, drug interactions, and toxicity)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (without explicit pharmacotherapy curriculum)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Overall student feedback
Number of subjects: 148
Study: 21863028

Group type: EXPERIMENTAL
Intervention: Focal therapy
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Criteria for focal prostatic ablation
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Surgical specimens analysis
Number of subjects: 525
Study: 18042559

Group type: EXPERIMENTAL
Intervention: Epidural administration of ropivacaine 2 mg ml(‐1), sufentanil 0.5 microg ml(‐1), clonidine 3 microg ml(‐1), and S(+)‐ketamine 0.25 mg ml(‐1) before incision (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline before operation, study solution started at the end of surgery (Group 2)
Number of subjects: 30
Study: 16595217

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional in vitro fertilization (IVF)
Number of subjects: 106

Group type: COMPARATOR
Intervention: IVF- group (IVF only)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: IVF+ group (IVF and ICSI)
Number of subjects: 106
Study: 12964892

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin 3.9 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral oxybutynin or oral tolterodine
Number of subjects: 0
Study: 10715641

Group type: EXPERIMENTAL
Intervention: JI bypass
Number of subjects: 18
Study: 9189773

Group type: EXPERIMENTAL
Intervention: Video defecography interpretation by four independent observers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Video defecography overall accuracy
Number of subjects: 100
Study: 1300436

Group type: EXPERIMENTAL
Intervention: Furosemide (mean dose 110 mg) intravenously 30 min prior to contrast injection
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group received fluids (mean 3 liters)
Number of subjects: 18
Study: 2859728

Group type: EXPERIMENTAL
Intervention: Desmethyldiazepam (from clorazepate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31756267

Group type: EXPERIMENTAL
Intervention: Standardized anaerobic high‐intensity interval training plus online lifestyle coaching program
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Online lifestyle coaching program only
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 40
Study: 29704641

Group type: EXPERIMENTAL
Intervention: Chronically raised plasma C-reactive protein (CRP)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Chronically raised plasma C-reactive protein (CRP) in ApoE ε4 carriers
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: High CRP (>3 mg/l ≤ 10 mg/l) as an isolated reading
Number of subjects: 259
Study: 27273977

Group type: EXPERIMENTAL
Intervention: Descemet's stripping automated endothelial keratoplasty (DSAEK)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cataract surgery (control group)
Number of subjects: 41
Study: 24166468

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23176887

Group type: EXPERIMENTAL
Intervention: Salbutamol (2 puffs of 100 μg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 20332357

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 18342964

Group type: EXPERIMENTAL
Intervention: 7-days-a-week postoperative continuous irradiation (p-CAIR)
Number of subjects: 279

Group type: COMPARATOR
Intervention: 5-days-a-week postoperative radiotherapy (CF)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: 7-days-a-week postoperative continuous irradiation (p-CAIR) in oropharynx/oral cavity subset
Number of subjects: 279

Group type: COMPARATOR
Intervention: 5-days-a-week postoperative radiotherapy (CF) in oropharynx/oral cavity subset
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: 7-days-a-week postoperative continuous irradiation (p-CAIR) in larynx subset
Number of subjects: 279

Group type: COMPARATOR
Intervention: 5-days-a-week postoperative radiotherapy (CF) in larynx subset
Number of subjects: 279
Study: 16398044

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (no radiofrequency ablation)
Number of subjects: 91
Study: 12131282

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg daily
Number of subjects: 8113

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 8113
Study: 10408550

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (Avonex)
Number of subjects: 0
Study: 7805271

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with one or more TIAs in the past 6 months and carotid stenosis ≥70%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with mild stroke within 6 months and carotid stenosis ≥70%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with TIAs within the past 6 months and stenosis 50% to 69%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with progressive stroke and a stenosis ≥70%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic patients with mild or moderate stroke in the past 6 months and a stenosis 50% to 69%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy ipsilateral to TIAs and a stenosis ≥70% combined with required coronary artery bypass grafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis >75% by linear diameter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis >60% as measured by diameter reduction (pending ACAS report)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with stenosis >75% in a high-risk patient/surgeon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic patients with ulcerative lesions without hemodynamically significant stenosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with moderate stroke with stenosis <50%, not on aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with single TIA, <50% stenosis, not on aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy for high-risk patients with multiple TIAs, not on aspirin, stenosis <50%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy for high-risk patients, mild or moderate stroke, stenosis <50%, not on aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with global ischemic symptoms with stenosis <50%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy for patients with acute dissection, asymptomatic on heparin
Number of subjects: 0